Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Janus kinase (JAK) inhibitors are widely used to inhibit inflammatory cytokine signaling in autoimmune and inflammatory diseases, but their effect on regulatory T cells (Tregs) is poorly characterized. We investigated the effect of a JAK inhibitor, upadacitinib, on human Treg differentiation and phenotype in comparison to BMS-986202, a selective Tyrosine kinase 2 (TYK2) inhibitor. Both upadacitinib and BMS-986202 blocked naive CD4 T cell differentiation into Th1/17 cells, but only BMS-986202 and a related TYK2 inhibitor, deucravacitinib, spared interleukin-2 (IL-2) signaling and Treg induction. BMS-986202 also increased Treg suppressive function and stability under Th1/17-polarizing conditions, whereas upadacitinib significantly impaired the phenotype and viability of ex vivo Tregs. In lamina propria mononuclear cells from patients with inflammatory bowel disease cultured under Th17-polarizing conditions, BMS-986202 redirected CD4 T cells toward a Treg phenotype. The Treg-sparing and enhancing properties of TYK2 inhibition suggest that TYK2 inhibitors are a promising pharmacological approach for tolerance induction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.xcrm.2025.102303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review of Phase III and Long-Term Data for Deucravacitinib for Plaque Psoriasis.
Int J Dermatol
August 2025
Department of Dermatology, Miller School of Medicine, Miami, Florida, USA.
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, represents a novel approach to systemic psoriasis treatment, offering the advantages of oral administration and selective inhibition of cytokine signaling pathways involved in psoriasis pathogenesis. This review evaluates the efficacy and safety of deucravacitinib based on findings from phase III clinical trials, including POETYK PSO-1, PSO-2, PSO-4, and long-term extension studies. In these trials, deucravacitinib demonstrated superior efficacy compared to placebo and apremilast, with a significantly higher proportion of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75).
View Article and Find Full Text PDFTYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation.
Cell Rep Med
August 2025
Department of Surgery, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada; School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada. Electronic address:
Janus kinase (JAK) inhibitors are widely used to inhibit inflammatory cytokine signaling in autoimmune and inflammatory diseases, but their effect on regulatory T cells (Tregs) is poorly characterized. We investigated the effect of a JAK inhibitor, upadacitinib, on human Treg differentiation and phenotype in comparison to BMS-986202, a selective Tyrosine kinase 2 (TYK2) inhibitor. Both upadacitinib and BMS-986202 blocked naive CD4 T cell differentiation into Th1/17 cells, but only BMS-986202 and a related TYK2 inhibitor, deucravacitinib, spared interleukin-2 (IL-2) signaling and Treg induction.
View Article and Find Full Text PDFWorking in negative space: Type I interferon mediated immuno-modulation through transcriptional suppression in disease and homeostasis.
Innate Immun
August 2025
Department of Microbiology and Immunology, University of Maryland, Baltimore (UMB), School of Medicine, Baltimore, MD, USA.
The type I interferon family of cytokines are rapidly produced following innate pattern recognition receptor engagement and establish a critical early state of host defense. Type I interferons act in antiviral immunity as transcriptional activators and the binding of any type I interferon to the common IFNAR receptor triggers the transcription of nterferon timulated enes (ISGs). A defined set of ISGs have been described through exhaustive studies and the protein products of these ISGs function to increase cell intrinsic resistance to viral growth and to promote viral clearance.
View Article and Find Full Text PDFTYK2 inhibition improves clinical and molecular hallmarks in various subtypes of cutaneous lupus.
Br J Dermatol
August 2025
Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Background: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease (ISD) with various clinical subtypes. Though the pathogenesis is not yet fully understood T cell mediated autoimmunity and elevated levels of type 1 interferons are two major factors contributing to the development of cutaneous lesions. Type 1 interferons transduce their signal via TYK2.
View Article and Find Full Text PDFDiscovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs.
J Med Chem
August 2025
National Chengdu Center for Safety Evaluation of Drugs, West China Hospital of Sichuan University, Chengdu 610041, China.
The development of selective JAK2 inhibitors represents a promising therapeutic strategy for MPNs. Building upon the foundation of our first-generation JAK2 inhibitor, we employed macrocyclization-driven structural optimization to address its off-target limitations. This strategy yielded a novel class of macrocyclic JAK2 inhibitors, with compound emerging as a standout candidate through systematic SAR studies.
View Article and Find Full Text PDF